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Integrins can exist in a range of functional states,  depending on the cell type and its state of 
activation. Although the mechanism that controls activity is unknown, it has been suggested 
that for some integrins, ot chain cytoplasmic domains may exert either a negative effect or no 
effect on  adhesion  function.  To  address  this  issue  for  VLA-4  (an  ot431 heterodimer),  we 
constructed  an  &  cytoplasmic  deletion  mutant  and  chimeric  ot  chains  composed  of the 
extracellular domains  of oe  4 and  the  cytoplasmic domains  of c~  2,  ot  4,  or  ots. Upon  stable 
transfection of wild-type c~  4, VLA-4 heterodimer was obtained that mediated (a) poor adhesion 
to CS1 peptide, fibronectin, or vascular cell adhesion molecule 1 (VCAM-1) (in K562 cells); 
(b) poor adhesion to CS1 peptide but moderate adhesion to VCAM-1  (in MIP101 cells);  and 
(c) moderate adhesion to  both  CS1  peptide  and  VCAM-1  (in  PMWK  cells).  Chimeric o~  4 
constructs and wild-type ot  4 yielded similar results in these cell lines.  In contrast,  truncation 
of the c~  4 cytoplasmic domain (after the conserved GFFKR motif) caused an almost complete 
loss of adhesive activity in all three cell lines. Thus, several interchangeable ot chain cytoplasmic 
domains play a fundamentally positive role in determining the state of constitutive activity for 
VLA-4. The ot chain cytoplasmic domain is also required for agonist-stimulated adhesion, since 
phorbol ester stimulated the cell adhesion mediated by wild-type and chimeric ol chains, but 
not by the cytoplasmic deletion mutant. The inactivity of both wild-type VLA-4 (in K562 cells), 
and truncated VLA-4 (in all three cell lines) was overcome by the addition of a stimulatory anti- 
31 monoclonal antibody. Thus, the ol cytoplasmic domain-dependent cellular mechanism con- 
trolling both constitutive and agonist-stimulated VLA-4 activity could be bypassed by external 
manipulation of the integrin. 
T 
he integrin family is comprised of at least 20 heterodimers, 
each with different ligand-binding specificities  formed 
by the pairing of one of 14 ot chains with one of eight 
chains. The ot4fll integrin VLA-4 has been implicated in a 
wide variety of biological processes. It is involved in cell adhe- 
sion to extracellular matrix via the alternatively spliced CS1 
domain of fibronectin (FN) 1 (1-4), and in cell-cell adhesion 
through the vascular cell adhesion molecule-1 (VCAM-1) on 
activated endothelium (3, 5, 6). VLA-4, which is normally 
expressed on  T  and  B  lymphocytes, monocytes,  and  eo- 
sinophils, is involved in inflammation, migration, and reck- 
culation of lymphocytes (7, 8). Eosinophil adhesion to acti- 
vated endothelium as seen in asthmatic and allergic conditions 
appears to be mediated by VLA-4 interaction with VCAM-1 
(9).  VLA-4/VCAM-1  interaction is likely to be important 
in lymphocyte adhesion to inflamed endothelium in rheu- 
1 Abbreviations used in this paper: FN, fibronectin;  pBS, pBluescript-KS  +  ; 
VCAM, vascular  cell adhesion molecule. 
matoid synovium (10-12).  Abs  against  the cr  integrin 
were shown to prevent the onset of experimental autoim- 
mune encephalomyelitis, suggesting that VLA-4 may be in- 
volved in inflammatory diseases of the central nervous system, 
such as multiple sclerosis (13). Differentiation of B lympho- 
cytes in germinal centers (14),  hematopoietic stem cells in 
bone marrow (15-17),  and T  lymphocytes in thymus (18), 
all involve interaction of VLA-4 with VCAM-1 or FN. Ad- 
ditionally, C~4fil  is expressed on neural crest-derived cells and 
interaction with the CS1 domain of FN is involved in migra- 
tion of those cells from the neural crest during embryogen- 
esis (19, 20). The VLA-4/VCAM-1 interaction has also been 
demonstrated during the formation ofmyotubes during muscle 
development  (21).  Because adhesion  through  c~431 is  in- 
volved in so many biological processes,  it follows that regu- 
lation of the adhesion mediated by ot4~1 (and other inte- 
grins) is of fundamental importance (22). 
Integrins are versatile,  exhibiting different levels of func- 
tional activity depending on the cell type and state of activa- 
tion (23-25). For example, on platelets and leukocytes, many 
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show increased binding capabilities after cell activation with 
a variety of agonists (23,  24, 26-30).  In contrast, on many 
other call types, integrins demonstrate a high level of func- 
tional activity, with relativdy little capability for further up- 
regulation (23, 24). Ehcidation of the mechanism(s) by which 
the functional activity of integrins is controlled is an area 
of intense research, and of fundamental importance. Nonethe- 
less, this mechanism is poorly understood, although it has 
been variously suggested that membrane lipid composition 
(31, 32), divalent cations (24, 33-35), integrin phosphoryla- 
tion (36-38), and glycosylation (39) may alter functional ac- 
tivity of integrin heterodimers. Other studies have suggested 
a role for the cytoplasmic domains of the integrin chains in 
the control of functional activity. Deletion of the t32, but 
not the ol  L, cytoplasmic domain resulted in loss of the ability 
to upregulate function by the phorbol ester PMA (40, 41), 
implicating the/3 but not c~ chain cytoplasmic domain in 
the control of functional regulation. AdditionaUy, it has been 
demonstrated that deletion of the o~  It~ cytoplasmic tail or ex- 
change with the c~  s cytoplasmic domain converted an inac- 
tive ~IIb~3 heterodimer to  a  highly functional state (42). 
This suggested that the c~  IIb cytoplasmic tail plays a nega- 
tive regulatory role, and thus, alteration of that domain resulted 
in upregulation of function. Heretofore, there has been min- 
imal analysis of the role of 13rassodated  ol chain cytoplasmic 
domains in the regulation of integrin-mediated adhesion. 
To analyze the role of the c~ chain cytoplasmic domains 
in the control of both constitutive and agonist-stimulated 
activity of ~  integrins, we have constructed a series of mu- 
tant o~ chains.  The cytoplasmic domain of ol  4 was  either 
deleted or exchanged with the cytoplasmic domains of ~2 
or c~  5,  and stable transfectants expressing these mutant od 
chains or wild-type o~  4 were assayed for adhesive function. 
For transfections, we chose three call lines (K562, MIP101, 
and PMWK) in which wild-type o~  4 was expressed to yield 
relatively inactive, partly active, or fully active VLA-4. Thus 
we were able to directly compare and determine the extent 
to which exchange or deletion of the cytoplasmic domain 
affects the variable levels of constitutive VLA-4 activity in 
different cell types. 
Materials  and Methods 
Abs, Antisera, Cell Lines, and Purified Ligands.  mAbs  used in 
this study were anti-cd, B-SG10 (43), and HP 1/2 (44); anti-~/l, 
A-1A5 (45) and TS2/16 (46); andJ-2A2 (47) was used as a negative 
control Ab. Peptides corresponding to the COOH-terminal 21 
amino acids of c~  2, and the COOH-terminal  21 amino acids of c~  4 
were coupled to KLH and injected into rabbits for generation of 
antisera as previously described (48). The primary  mdanoma 
PMWK (49) was a gift from Dr. H.R. Byers (Massachusetts  General 
Hospital, Boston, MA). The 40-kD fragment of FN-40, which 
contains the CS1 region, was purified as described (50). Recom- 
binant soluble VCAM-1 (51), the form with seven Ig domains, 
(sVCAM-1) was the gift of  Dr. Roy Lobb (Biogen  Inc., Cambridge, 
MA). CS1 peptide conjugated to BSA (CS1-BSA) was the gift of 
Dr. T. Shimo-Oka (Iwaki Glass Co., Tokyo, Japan). 
Construction of Chimeric c~ Chains, Transfection, and Cell Cul- 
tur~  Mutations introducing a HindIII site into cx  2 and ~  cDNAs 
were as described (52). The X4C2 chimeric c~ subunit was first 
constructed in pBluescript-KS  + (pBS) by excising the 3' 1.3 kb of 
the cd cDNA using KpnF  s~ and XbaI~ p*~  and then inserting 
the 516-bp KpnFS27-HindlII  ~3 fragment of cr 4 and the  1.9-kb 
Hindiip512.XbaiPBs voly~;~  fragment of c~  2. For construction of the 
X4C5  chimera, the 0.7-kb HindlII~7-XbalP  ss polylinker  fragment 
from the cr s cDNA was used instead of the 1.9-kb fragment of 
~2. The cd cDNA containing the introduced HindIII site (X4C4) 
encodes an  c~  4 protein  with  a  single conservative amino  acid 
change from alanine to leucine at amino acid number 969. The 
cd cytoplasmic  deletion mutant (X4CO) was created by replacing 
codons for Q97S and y976 (CAA, TAC) with termination codons 
(TAA, TAG) after the highly conserved  GFFKK motif  in the cyto- 
plasmic domain of the integrin c~  4 cDNA using a PCK mutagen- 
esis procedure (53). Sequendng of  the product confirmed that only 
the intended mutations were introduced into the cDNA. The con- 
structs were cloned into the pFNeo (54, 55) or pSRc~Neo expres- 
sion vector using the SalI and XbaI sites present in the pBS poly- 
linker. The latter vector is a composite of pStLcx (56) and pFNeo, 
prepared by Dr. Humid Band (Brigham and Women's Hospital, 
Boston, MA; manuscript in preparation). K562 (erythroleukemia), 
MIP101 (colon carcinoma), and PMWK (primary melanoma)  were 
chosen as cr 4 recipients because they do not normally express 
VLA-4. K562 cells were transfected via electroporation at 960 ~F 
and 270 mV using a gene pulser (Bio-Rad  Laboratories,  Cambridge, 
MA). Constructs were transfected into MIFI01 and PMWK cells 
using  the  Lipofectin reagent  (Betbesda Research Laboratories, 
Bethesda, MD).  After selection with 2.0-mg/ml  G418 (Gibco, 
Grand Island, NY), resistant cells were enriched for c~  4 expression 
using the B-5G10 mAb and immunomagnetic beads (Dynal, Inc., 
Great Neck, NY). Stably transfected cells were cultured in RPMI 
1640 supplemented with 10% FCS L-glutamine, antibiotics, and 
1.0 mg/ml G418 (complete media). 
Flow Cytometry and lramunoprecipitations.  Indirect  immuno- 
fluorescence was performed as described (3). For immunoprecipi- 
ration, lactoperoxidase  and ~zsI were used for cell surface labeling 
followed  by lysis  with 1% Triton X-100 in Tris-buffered  saline. Im- 
munoprecipitation  and SDS-PAGE were carried out as described  (57). 
Adhesion Assays.  Adhesion  assays  were essentially  as described 
(58). Briefly,  ceUs were labeled by incubation with the fluorescent 
dye BCECF-AM (Molecular Probes, Inc., Eugene, OK), and then 
5 x  104 cells in ILPMI with 0.1% BSA (assay media) were added 
to each well of 96-well microtiter plates (Flow Laboratories, Inc., 
McLean, VA) that had been coated  with protein ligands and blocked 
with 0.1% BSA. After 20-rain incubation at 37~  unbound cells 
were removed (two to three washes with assay media). Ceils re- 
maining attached to the plate were analyzed using a fluorescence 
concentration analyzer machine (IDEXX Co., Portland, ME), or 
Cytofluor  2300 (Millipore Corp.,  Bedford, MA).  Background 
binding (assessed using BSA-coated wells) was typically <5% of 
the total, and results are reported as the mean of triplicate determi- 
nations _+ SD. TS2/16 (1 #g/m1) or PMA (10 ng/ml) was added 
to indicated samples at the start of the assay. For assays  in which 
blocking Abs were used, cells were incubated with blocking or 
control Abs for 30 rain before the time of plating. 
Results 
Chimeric  cx Chains Associate with {31 and Are Expressed on 
the Cell Surface.  To examine the role of the o~ chain cyto- 
plasmic domain in control of integrin function, a series of 
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Figure  1.  Schematic  diagram of truncated and chimeric cx chain con- 
structs. The extracellular  and transmembrane  domains for each construct 
were derived from the off (diagonal stripes) cDNA, the cytoplasmic  do- 
mains were derived from ~2 (open),  c~  4 (diagonal stripes), or o~  s (stippled) 
cDNAs (see Materials and Methods). (Lower case letters) Wild-type and 
mutated nucleotide  sequence. Single  letter amino  acid  code (ul~ercase letters) 
is used to denote the wild-type and mutant protein sequence beginning 
from the lysine  immediately  inside  the putative transmembrane sequence. 
Mutations in both the nucleotide as well as the protein sequence are in 
parentheses. 
truncated and chimeric cb molecules were created (Fig.  1) 
and stably expressed at the cell surface ofK562, MIP101, and 
PMWK cells (Fig. 2). Notably, the chimeric molecules (X4C2 
and X4C5) were expressed at roughly similar levels as unal- 
tered c~  4 (X4C4), whereas ob lacking a cytoplasmic domain 
(X4C0)  was expressed at variably lower levels.  Expression 
of fl~ in K562 cells was increased slightly upon transfection 
of the c~ chain constructs, although no significant differences 
in B~ expression were seen in the MIPI01  or PMWK cell 
lines because of the large number of ~  chains endogenously 
expressed. 
/~1 can form a  stable heterodimer with each of the chi- 
meric c~ chains, as shown by coprecipitation of the c~ chi- 
mera with/~t-specific mAbs  (Fig.  3,  lanes e,  i,  m,  and q) 
as well as coprecipitation  of Bt with  the od-specific mAb 
B-5G10 (Fig. 3, lanesf, j, n, and r). Also coprecipitating with 
/~1 was c~  s, seen as a faint band at ,x,150 kD  (Fig. 3, lanes 
a, e, i, m, and q). The presence of this other integrin partly 
accounts for the level of total/~ being greater than the level 
of/~t associated with off. Identity of the chimeric ob chains 
was confirmed using antisera recognizing specific cytoplasmic 
tails. Antisera raised against a peptide from the cytoplasmic 
domain  of o~  ~ precipitated  chimeric  proteins  from  X4C2 
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Figure 2.  Flow  cytometry profiles of cells transfected  with chimeric 
or truncated ob constructs. K562 (column  1), MIPI01 (column  2),  and 
PMWK (column 3) cell lines transfected  with vector alone (row 1), or the 
vector containing the X4CO (row  2), X4C2 (row  3), X4C4 (row 4), X4C5 
(row  5) constructs were analyzed  for surface expression of o~  4 and fll by 
flow cytometry. The J2A2 mAb (solid line) was used as a negative  control 
antibody (-), B5G10 (large dotted line) was used to determine  surface  levels 
of ~4 and A-1A5 (small dotted line) was used to determine surface levels 
of ill. Fluorescence  intensity is shown in logarithmic scale, and 3,000- 
5,000 cells were measured to yield each histogram. 
transfected cells (Fig. 3, lane h) but not from pFNEO, X4C4, 
X4C5,  or X4C0 transfected cells (Fig. 3, lanes d, I, p, and 
t). Similarly, antisera raised against a peptide from the ~4 cy- 
toplasmic domain precipitated proteins from cells transfected 
with X4C4 (Fig. 3, lane h) but not from pFNEO,  X4C2, 
X4C5, or X4C0 constructs (Fig. 3, lanes c, g, o, and s). These 
results demonstrated that substitution of the cytoplasmic do- 
main of o~  4 did not alter heterodimer assembly or expression. 
Although the X4C0 mutant was expressed in association with 
Bt, deletion of the ol  4 cytoplasmic domain consistently re- 
sulted in lower expression (Fig. 2), perhaps because of slightly 
altered heterodimer assembly or stability. Exchange or dele- 
tion of the cytoplasmic domain did not alter the ability of 
c~  4 to be processed into its various structural forms (59).  In 
K562 cells, wild-type and modified c~  4 chains were all equally 
cleaved into o~  4/s~ and ob n~ fragments (Fig.  3).  The ob/7~ 
fragment (derived from the COOH-terminal portion of oz  4) 
of X4C0 migrates at a lower apparent molecular weight (Fig. 
3, lanes q and r) than the same fragment of X4C4 (Fig. 3, 
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cated ot chains in K562. Transfectants KpfNEO (lanes a-d), 
KX4C2 (lanes e-h), KX4C4 (lanes i-/), KX4C5 (lanes m-p), 
and KX4C0 (lanes q-t) were surface labeled with 12sI and ex- 
tracted with 1% Triton X-100 in TBS. Immunopreeipitations 
were carried out with mAb A-1A5 (BI) in lanes a, e, i, m, 
and q; mAb B-5G10 (od) in lanes b,f,j,  n, and r; rabbit an- 
tisera to the cytoplasmic domain of ot  4 (oOC) in lanes c, g, 
k, o, and s; or rabbit antisera to the cytoplasmic domain of 
~x  z (cdC) in hnes d, h, t, p, and t, and analyzed by SDS-PAGE 
(7%  acrylamide) followed by autoradiography.  Molecular 
weight  standards (left);  labeled protein  species (right). 
lanes i-k) consistent with deletion of the COOH-terminal 
25 amino acids. In MIP101  and PMWK transfectants,  the 
appearance of the c~  4/1s~  and od/is~ structural forms (60), was 
not altered  by cytoplasmic domain modification (data  not 
shown). The 0/4B7 complex, examined by flow cytometry 
using the Act-1 mAb (61), was not detected on K562, MlPl01, 
or PMWK transfectants,  consistent with 0/4 being entirely 
associated with ~1. 
Variable Constitutive Activity  of VLA-4  in  Different  Cell 
Types.  K562, MIP101, and PMWK transfectants expressing 
X4C4 were assayed  for their basal levd of adhesion to sVCAM-1 
and to CS1-BSA. Although surface expression of VLA-4 on 
each of these transfectants was similar, they exhibited widdy 
variable adhesive properties (Fig. 4 A). Without stimulation, 
K562-X4C4 transfectants showed very little binding to ei- 
ther CS1-BSA or sVCAM-1, the MIP101-X4C4 transfectants 
displayed low level adhesion to CS1-BSA yet moderate adhe- 
sion to sVCAM-1, and the PMWK-X4C4 transfectants  ex- 
hibited substantial adhesion to both ligands. Adhesion of each 
cell line was differentially  amplified  after  stimulation with 
the TS2/16 mAb (previously shown to enhance B1 integrin 
mediated adhesion [23, 24, 62, 63]). Cell adhesion to sVCAM-1 
was enhanced by 9.9, 3.0, and 1.4-fold (K562, MlPl01, and 
PMWK,  respectively),  and cell adhesion to CS1-BSA was 
stimulated by 26.8, 6.6, and 1.4-fold  (K562,  MIP101,  and 
PMWK, respectively) (Fig. 4 B). Thus we conclude that the 
K562 cell line had low constitutive activity but had a high 
potential for stimulation, the MIP101 cell line had an inter- 
mediate level of constitutive activity and moderate potential 
for stimulation, and the PMWK call line had high constitu- 
tive activity with a low capacity for further stimulation. In 
several other experiments (data not shown), the magnitude 
of stimulation within each cell line was variable but the trend 
was consistent. Thus ol  4 derived from a single cDNA ex- 
pressed in different cellular  environments resulted in 014~1 
with different levels of constitutive activity.  As previously 
demonstrated, endogenous 0/4~1 can exist in a range of func- 
tional states depending on the cellular environment, and the 
degree of stimulation is inversely proportional to the basal 
level of activity (24). This is analogous with results obtained 
with 0/Z-transfected  ceils demonstrating differential ability to 
bind to collagen and laminin (23). 
Because PMWK cells showed substantially more consitu- 
tive adhesion to VLA-4 ligands than did K562 cells, it was 
considered that these cell types could differ in their general 
overall adhesivity, independent of VLA-4 function. However, 
this was not the case because adhesion of PMWK cells was 
not greater than K562 cells on poly-t-lysine (Fig. 5 B), and 
both showed similarly low adhesion to BSA (Fig. 5 A). Fur- 
VCAM-1  ~]  CS-1 
I  ~  ￿9  CS-1(TS2/16) 
PMWK ~  ￿9 cs-1 
MIP101 ~ 
K562 
1DD  20D  300  400  5000  10  20  30 
A  Cells  bound / mm2  a  Stimulation  Index 
Figure 4.  Adhesion of X4C4 transfected cell lines to CSI-BSA and 
sVCAM-1 is variable and affected  by stimulation to different degrees. (Left) 
Adhesion of X4C4 transfectants to CS1-BSA and sVCAM-1, both at a 
coating concentration of 2.5 #g/ml, was assayed in the absence or pres- 
ence of mAb TS2/16 (1 #g/ml) as described in Materials and Methods. 
CS1-BSA (Jilled), CS1-BSA  plus TS2/16 (gray  crosshatch), sVCAM-1  (unfilled), 
and sVCAM-1 plus TS2/16  (diagonal stripes). (Right)  Stimulation index 
was calculated as (adhesion in the presence of TS2/16)/(adhesion  in the 
absence of TS2/16),  and plotted for both CS1-BSA (gray crosshatch) and 
sVCAM-1 (diagonal stripes). 
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Figure  5.  Comparison  of (x4fll-transfected  K562  and  PMWK  cell 
adhesion to control surfaces. Adhesion of K562 and PMWK transfectants 
was determined  as described in Materials and Methods,  except that back- 
ground binding was not subtracted.  K562 and PMWK cell lines  trans- 
fected with X4C0 (filled)  or X4C4 (diagonal stripes)  were examined  for 
their adhesion  to plastic surfaces coated with 0.1% heat-denatured BSA 
(A) or 5 #g/ml poly-t-lysine (B). 
thermore, in these control experiments,  there was essentially 
no difference between X4C0 and X4C4 contructs, despite 
their  marked differences in mediating adhesion to VLA-4 
ligands (see Figs.  6-8). 
Functional Activity of ot~l~l: Dependence on the identity of the 
Cytoplasmic Domain.  It has been suggested that deletion or 
substitution of the cr chain cytoplasmic  domain can release 
an integrin from an inactive  conformation and allow it to 
display adhesive function (42). To determine how the iden- 
tity of the c~ chain cytoplasmic tail affected the level of con- 
stitutive  function of the  ot4/~1 integrin  heterodimer,  cells 
transfected  with cd chimeras  were tested  for  adhesion to 
sVCAM-1  and CS1-BSA  in a standard adhesion assay (58). 
Dose-dependent adhesion of all transfectants to sVCAM-1, 
CS1-BSA, or to a 40-kD fragment of FN containing the CS1 
region (FN-40) was VLA-4 specific, as evidenced by nearly 
complete inhibition by the o~4-specific  antibody HP1/2 (data 
not shown). Additionally,  mock transfectants displayed only 
minimal binding to either  ligand. 
Adhesion of K562 transfectants was uniformly low at the 
lower doses of FN-40 (0-20 #g/ml) and sVCAM-1  (0-2.5 
#g/ml), regardless of the cytoplasmic  domain (Fig. 6, A  and 
B). Thus replacement or removal of the cytoplasmic  tail of 
~4 did not lead to increased constitutive activity of VLA-4. 
At higher doses of FN-40 (>20/~g/ml,  data not shown) or 
sVCAM-1  (>2.5 #g/ml)  a moderate  level of adhesion was 
observed, but still there was no consistent difference between 
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Figure  6.  Dose-dependent  adhesion oftransfec- 
rants to ligand..Adhesion of transfectants to a range 
of ligand concentrations  was determined  as de- 
scribed in Materials  and  Methods.  Adhesion of 
K562 transfectants to FN-40  (A) and sVCAM-1 
(B),  MIP101 transfectants  to  CS1-BSA  (C)  and 
sVCAM-1 (D), and PMWK transfectants to CS1- 
BSA (E) and sVCAM-1 (F) are results of represen- 
tative  experiments.  Adhesion of each  individual 
transfectant  demonstrated  variability,  however 
results presented in a single pand were derived from 
a single assay. cells transfected with the different chimeric c~  4 constructs. 
However, at the higher ligand doses (sVCAM-1 5/xg/ml) 
a lower level of adhesion was mediated by X4C0 than by 
X4C4,  X4C2,  or X4C5 in K562 cells. It appears  unlikely 
that the slightly lower level of surface expression of the X4C0 
construct could account for the greatly diminished adhesion 
at the high ligand level. When tested for adhesion to CS1- 
BSA (data not shown), the panel of K562 transfectants yielded 
results very similar to those obtained using FN-40. 
For MIP101 and PMWK transfectants, the functions of 
the X4C4,  X4C2,  and X4C5  constructs were again not 
markedly different from one another (Fig. 6, C-F). Multiple 
other experiments (data not shown) confirmed that each of 
these constructs supported adhesion essentially to a similar 
extent, with minor variations perhaps due to slightly different 
expression levels. 
In marked contrast to the chimeric constructs, the trun- 
cated ot  4 (X4C0)  supported essentially no adhesion above 
that seen with mock-transfected MIP101 and PMWK cells 
(Fig. 6, C-F). Although cell surface expression of X4C0 was 
at a slightly lower level in those cells (Fig. 2), the nearly com- 
plete absence of adhesion appeared to be greater than could 
be explained by lower expression. 
To test whether variation in expression levels caused the 
differences seen in levels of adhesion, cell surface expression 
of chimeric ot  4 chains and cd-mediated adhesion were exam- 
ined in parallel,  and then flow cytometry results were used 
to normalize adhesion results.  Upon dividing cell adhesion 
(cells bound/mm  2) by c~  4 expression (mean fluorescence in- 
tensity units [MFI]), we obtained a normalized result that 
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Figure  7.  Normalization of adhesion for cell surface expression of chi- 
meric and truncated ot  4 chains in transfected cell lines.  Adhesion assays 
and flow cytometry analyses were as described in Materials and Methods. 
These assays were done concurrently for greater accuracy in normaliza- 
tion. For K562, the mean of three experiments for CS1-BSA (5.0/~g/ml) 
is presented, whereas for MIP101 and PMWK the mean of four experi- 
ments (two for sVCAM-1 at 2.5/~g/ml and two for CS1-BSA at 2.5/~g/ml) 
are presented.  Adhesion was measured as cells bound/mm  2 and od expres- 
sion was calculated  by subtraction of the mean fluorescence intensity of 
a negative control mAb (J2A2) from the mean fluorescence  intensity of 
an cd mAb (B-SG10). 
clearly showed that adhesion mediated by c~4B1 was not al- 
tered by exchange of the cytoplasmic tail (Fig.  7).  As indi- 
cated, whether constitutive activity was low (K562), inter- 
mediate (MIP101),  or high (PMWK),  similar normalized 
results were obtained using X4C2,  X4C4,  or X4C5. 
However, even after normalizing for expression differences, 
the X4C0 construct yielded substantially lower adhesive ac- 
tivity in both MIP101  and PMWK cells. In K562 cells, the 
adhesive activity of VLA-4 was already at such a low level, 
that truncation of the cytoplasmic domain could not result 
in a further decrease in activity. 
To verify that the normalization of adhesion to cell surface 
expression was valid over a range of expression levels, we ex- 
amined a series of six MIP101-X4C4 clones and lines,  and 
compared their adhesion to either CS1-BSA  or sVCAM-1, 
with their surface expression of c~  4. It was apparent that over 
a wide range of expression levels, adhesion to sVCAM-1 (Fig. 
8 A) and to CS1-BSA  (Fig.  8 B) correlated well with cell 
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Figure  8.  Normalization of cell adhesion for expression  of X4C4 in 
MIP101  cell clones  with different  levels of c~4 expression.  Adhesion to 
sVCAM-1 (5.0 #g/m1) and CS1-BSA (5.0 #g/ml) and cell surface expres- 
sion were determined concurrently as described in Materials and Methods. 
In each graph cell adhesion (sVCAM-1, top and CS1-BSA, bottom)  is plotted 
on  the ordinate, whereas  the  o~  4 specific mean fluorescence  intensity 
(MFIBSCI~  TM) is plotted on the abscissa. The data from six X4C4 
transfected MIP101 dones and lines result in a linear correlation defined 
by y  =  13.770  +  6.9345X, K 2 =  0.913 for sVCAM-1, and y  =  7.0733 
+  2.5843X,  K 2 =  0,831 for CS1-BSA. Adhesion of several MIFI01-X4C0 
cell lines is also plotted (O). 
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was ~mamined in  assay  media alone  0ql/ed), assay 
media in the  presence  of  I/~g/ml ot4-blocking 
mAb HP1/2 (gray crosshatch),  assay media in- 
cluding 1 #g/ml TS2/16 (diagonal stripes),  or 
assay media including 1 #g/ml TS2/16 and 1 
#g/ml HPl/2 (tire tread).  (.4)  K562 transfec- 
taut adhesion to sVCAM-1 (10 /~g/ml).  (B) 
MlPl01 transfectant adhesion to sVCAM-1  (5.0 
#g/ml). (C) PMWK transfectant adhesion to 
sVCAM-1 (2.5 #g/ml). 
surface expression of c~  4.  In addition,  MIP101-X4C0  cells 
showed notably lower levels of adhesion to both CS1-BSA 
and to sVCAM-1 than would be predicted based on c~  4 ex- 
pression (Fig.  8, A  and B), providing further evidence that 
the loss of cell adhesion was due to the deletion of the o~  4 
cytoplasmic domain, and not to low surface expression of 
X4C0. 
Ab Stimulation of or Chain Cytoplasmic Deletion Mutants.  To 
determine whether o: cytoplasmic deletion mutants had an 
inherent defect that prevented them from binding ligand under 
any circumstance, we tested their ability to adhere to sVCAM-1 
after stimulation by the anti-~l mAb TS2/16 (23,  24,  62). 
Whereas there was minimal unstimulated activity for the 
X4C0 construct in K562 (Fig.  9 A), MIP101 (Fig.  9 B), or 
PMWK cells (Fig. 9 C), TS2/16 stimulation caused a greatly 
elevated level of adhesion in each case. Also, the low (Fig. 
9 A) or intermediate (Fig.  9 B) activity or the X4C4 con- 
struct was greatly elevated by TS2/16 stimulation. In PMWK 
cells (Fig. 9 C) X4C4 was already active, and therefore only 
slightly stimulated. For each cell line, adhesion (unstimulated 
or stimulated) was entirely blocked by HP1/2, indicating that 
it was VLA-4 mediated. When adhesion to CS1-BSA  was 
examined, similar results were obtained (data not shown). 
The nearly identical activities of X4C0 and X4C4 in the pres- 
ence of TS2/16 emphasizes again (as also seen in Fig. 5) that 
there is no difference in the overall adhesive properties of the 
transfected cells. Also, this result emphasizes that when VLA-4 
is fully stimulated, there is no difference in the specific adhe- 
sive contributions of X4C4  and X4C0. 
Phorbol Ester Stimulation of  Adhesion: Affect of or Chain Cy- 
toplasmic Domain.  As it is known that cell stimulation with 
a variety of agonists results in enhanced ~1 integrin-mediated 
adhesion (22, 64, 65), we sought to ascertain the role of the 
ee chain cytoplasmic domain in agonist-stimulated adhesion. 
Adhesion of X4C0 and X4C4 transfectants to both CS1-BSA 
and sVCAM-1 was assayed in the presence of PMA (a model 
cellular agonist) or TS2/16, and results are shown in Fig. 10. 
Predictably, each of the cell lines transfected with X4C4 exhib- 
ited increased cell adhesion to either CS1-BSA or sVCAM-1 
in response to either PMA and TS2/16. Notably, there was 
variable enhancement of cell adhesion in response to PMA, 
with the K562-X4C4 transfectant showing a high degree of 
stimulation, MIP-X4C4 exhibiting an intermediate increase 
in  adhesion,  and  PMWK-X4C4  displaying only slightly 
elevated adhesion.  In this  regard,  stimulation with PMA 
resembles that seen with TS2/16 in Fig. 4.  In contrast to 
the X4C4 transfectants, none of the X4C0-bearing cell lines 
exhibited enhanced adhesion in response to PMA, although 
they all demonstrated markedly increased adhesion in response 
to TS2/16. These data suggest that the cytoplasmic domain 
of the ot chain is critically involved in the stimulation of adhe- 
sion by a cellular agonist such as PMA. 
To further examine the role of oe chain cytoplasmic do- 
mains in agonist-stimulated adhesion, cell lines expressing 
chimeric o~ chains were assayed for sensitivity to PMA and 
to TS2/16. To help control variability in absolute levels of 
adhesion, results were expressed in three ratios: (a) adhesion 
in the presence of PMA divided by adhesion in normal media; 
(b) adhesion in the presence of TS2/16 over adhesion in the 
presence of assay media; and (c) adhesion in the presence of 
PMA over adhesion in the presence of TS2/16 (maximal adhe- 
sion). These three ratios were determined for each separate 
experiment, and the mean and SD of ratio values from mul- 
tiple experiments are presented in Table  1. In all three cell 
lines, the PMA/media and PMA/TS2/16 ratios were notably 
diminished for X4C0- compared to X4C4-transfected cells 
(values,  *). Thus truncation of the oe cytoplasmic domain 
clearly  resulted  in  loss  of response  to  PMA.  Also,  the 
PMA/media and PMA/TS2/16 ratios from X4C2,  X4C5, 
and X4C4  transfectants were not significantly different in 
any of the three cell types. Therefore substitution of the a 2 
or e: tail did not alter the affect of either PMA or TS2/16 
on cell adhesion. Together, these results imply that the ee 
cytoplasmic domain is critically involved in agonist-stimulated 
adhesion, but the identity of the domain is not crucial. The 
PMA/media ratio for adhesion to sVCAM-1 did not appear 
to be decreased for the X4C0 transfected MIP101 or PMWK 
cell lines.  However this may be due to the very low levels 
of initial binding seen by these cells. When the PMA/TS2/16 
ratios for these cell lines are compared, it is dear that PMA 
stimulation did not enhance adhesion to the levels seen with 
the X4C4  transfected cell lines. 
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Figure  10.  Agonist-stimulated 
adhesion of X4C0 and X4C4 trans- 
fected cell lines. K562 (A and B), 
MIP101 (C and D), and PMWK (E 
and F) transfectants were assay~xi  for 
adhesion to CS1-BSA or VCAM-1 
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in Materials and Methods. Coating 
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BSA at 10 #g/ml (A), 5/~g/ml (C), 
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Discussion 
This study clearly demonstrates a role of the c~ chain cyto- 
plasmic  domain  in  regulation  of constitutive  avidity  and 
agonist-stimulated  activity of a  prototype  ~t  integrin  het- 
erodimer,  VLA-4.  First,  we  established  that  the  same  ot  4 
cDNA  expressed  in  three  different cell types yielded three 
distinct  levels of activity.  Second,  we found  that  exchange 
of the o~  4 cytoplasmic tail with that of o~  2 or ct  s had no effect 
on  the  level  of constitutive  activity  of the  oL4B1 integrin 
Table  1.  PMA and TS2/16  Stimulation of Transfected Cell Lines 
CS1-BSA  sVCAM-1 
PMA  TS2/16  PMA  PMA  TS2/16  PMA 
Cell 
line  n  Media  Media  TS2/16  n  Media  Media  TS2/16 
K562 
X4C0  8  *0.52  +  0.40  7.60  _+  6.50  *O.ll  _+  0.14  6  *0.72  _+  0.69  3.74  +  2.83  "0.31  _+  0.33 
X4C2  8  9.78  _+  11.56  15.58  _+  15.37  0.61  _+  0.37  6  3.71  +_  2.71  4.60  +_  3.63  0.88  _+  0.16 
X4C4  8  13.25  +  14.14  30.69  _+  22.27  0.45  +  0.24  6  2.99  +_  1.89  5.43  +  3.47  0.67  +  0.31 
X4C5  8  4.27  _+  2.85  22.68  _+  23.92  0.26  _+  0.09  6  2.30  +_  2.48  7.14  +  11.94  0.56  _+  0.30 
MIP101 
X4C0  3  *0.30  +  0.42  5.78  _+  5.94  *0.02  _+  0.04  7  1.29  +_  1.00  15.83  +  14.06  *0.29  +  0.47 
X4C2  3  1.70  +_  0.19  3.26  _+  1.16  0.59  _+  0.31  3  1.05  _+  0.29  1.87  _+  0.67  0.63  _+  0.28 
X4C4  3  1.74  +  0.23  4.66  +_  4.14  0.56  +_  0.31  3  1.59  +_  0.56  3.06  +  2.40  0.68  +  0.27 
X4C5  3  1.48  +  0.37  3.63  _+  2.65  0.52  _+  0.27  3  0.96  _-!- 0.12  1.53  _+  0.57  0.67  +  0.19 
PMWK 
X4C0  7  "0.51  _+  0.87  3.42  +_  3.14  "0.16  _+  0.23  6  2.47  _+  1.78  22.16  +  18.96  *0.11  _+  0.12 
X4C2  7  2.24  _+  1.72  2.29  _+  1.19  0.97  _+  0.37  6  1.13  +  0.06  1.19  _+  0.10  0.95  _+  0.05 
X4C4  7  1.48  _+  0.41  1.83  _+  0.87  0.87  _+  0.16  6  1.35  _+  0.32  1.53  _+  0.39  0.89  _+  0.05 
X4C5  7  1.67  _+  0.51  1.72  _+  0.52  0.99  +_  0.17  6  1.28  +_  0.48  1.37  _+  0.57  0.95  +  0.11 
Adhesion assays were as described in Materials  and Methods. The PMA/media ratio was determined  by dividing the adhesion  (cells bound/mm 2) 
in the presence of PMA by the adhesion  in the presence of assay media alone.  The (TS2/16)/(media) ratio was calculated by dividing adhesion in 
the presence of TS2/16 by adhesion in assay media, and the (PMA)/(TS2/16) ratio was computed by dividing the adhesion in the presence of TS2/16 
by the adhesion  in the presence of PMA. Ratios from multiple experiments  were averaged and presented  as the mean  +-  SD. Values in bold-face 
type demonstrate significant  differences (p <  0.01,  Student's t test)  when compared  with values for X4C4 transfectants. 
* Discussed  in text. 
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(MIP101 cells), or high (PMWK  cells). Third, deletion of 
the ot  4 cytoplasmic domain led to greatly diminished adhe- 
sion relative to that observed using X4C4 or the chimeras 
(X4C2,  X4C5).  This diminished activity (X4C0  mutant) 
was especially obvious in both the MIP101 and PMWK cell 
lines, and was not merely a result of lower expression. Fourth, 
cell stimulation with a model cellular agonist (PMA) was 
able to upregulate integrin-mediated adhesion regardless of 
which cytoplasmic tail (c~  2,  ot  4,  or c~  s) was used, whereas 
truncation of the cytoplasmic tail eliminated the capability 
of PMA to stimulate cell adhesion. A fifth major finding in 
this work is that the anti-81 mAb TS2/16 could stimulate 
adhesive function of all three cells bearing the X4C0 con- 
struct. Thus, whereas the absence of a cytoplasmic domain 
may disable the "natural" mechanism for generating a func- 
tionally active integrin, this mechanism can be bypassed by 
direct action of the TS2/16 mAb on the integrin. Notably, 
the natural constraints on integrin function in K562 cells ex- 
pressing X4C4 were similarly bypassed through the addition 
of TS2/16. 
Although results presented here strongly suggest that sev- 
eral interchangeable oL chain cytoplasmic domains play a posi- 
tive role in regulating cell adhesion,  studies involving the 
cr cytoplasmic domains of other integrins have yielded con- 
fusing and dissimilar results. The cytoplasmic domain of ot  xlb 
appeared to play a negative regulatory role because deletion 
or  exchange  of the  c~  lIb tail  with  that  of c~  s  caused  the 
affinity of the c~"b33 complex for its ligand to increase (42). 
In a separate study, the cytoplasmic tail of c~  L was truncated 
with no apparent alteration of the adhesive properties of the 
C~I'82 heterodimer (40, 41),  suggesting that the ol chain cy- 
toplasmic domain has no effect on the level of constitutive 
avidity of the 82 integrin. There are several possible reasons 
why our results are contrary to those found with the c~  Itb 
and cr r integrin subunits. First, the cells transfected in those 
studies were different than those in our study, and it is be- 
coming increasingly evident that integrins behave differently 
in distinct cellular environments (23,  24,  66, 67).  Second, 
in the oL  lIb study, the o~  Hb cytoplasmic tail was truncated be- 
fore the highly conserved GFFKR sequence, whereas we have 
deleted ot  4 after that sequence. Third,  the cytoplasmic tail 
of c~  s was placed onto the ot  "b extracellular domain, forcing 
the unnatural association of the ots and 33 cytoplasmic do- 
mains, which could be responsible for the increase in ligand 
binding. Fourth, it is possible that integrin ot subunit cyto- 
plasmic domains are regulated in distinct ways depending on 
whether they are associated with 81, 32, or 33. This could 
explain why in three studies of ot cytoplasmic domains, in- 
volving three different 8  chain partners,  three distinct an- 
swers regarding regulation of constitutive activity were ob- 
tained. 
We do not know the mechanism whereby integrins are 
maintained in different states of constitutive activity in different 
cell types. Also, it is not clear how PMA stimulation causes 
a rapid upregulation in integrin function. Nonetheless, we 
propose that the regulation of constitutive activity and agonist- 
stimulated activity could have similar mechanistic elements 
because (a) neither is influenced by exchange of c~  4 with c,  2 
or c~  s cytoplasmic tails;  (b) both are suppressed upon cr 4 cy- 
toplasmic domain deletion; and (c) in both cases, the nega- 
tive effects of cytoplasmic domain deletion can be overcome 
by  the  addition  of  the  anti-B1  mAb  TS2/16.  Thus,  we 
hypothesize that PMA, on a rapid scale, introduces a change 
into cells (such as K562) that is already constitutively present 
in cells such as PMWK. 
It is quite clear that VLA-4-mediated cell adhesion varies 
in different cell types, is suppressed upon cytoplasmic tail de- 
letion, and is upregulated upon PMA treatment. However, 
it is not clear whether any of these changes are due to varia- 
tions in post-ligand binding events necessary for cell adhe- 
sion, or involve direct alterations in integrin-ligand binding 
affinity. 
In one model, cytoplasmic tail deletions or PMA treat- 
ment could alter integrin interaction with the cytoskeleton 
or other key proteins, and thus influence the overall cellular 
adhesiveness without changing ligand binding affinity. Con- 
sistent with  this,  agents  that  disrupt the cytoskeleton are 
known to cause diminished cell adhesion (62, 68, 69). Also, 
PMA stimulation of LFA-1 (ott3z) function correlated with 
codustering of LFA-1 with the cytoskeletal protein talin (70, 
71),  and PMA-treated macrophages showed increased cyto- 
skeletal anchoring (38),  Furthermore,  in one study, PMA 
stimulated increased cell adhesion to FN without altering 
the apparent affinity for soluble FN binding (64). 
On  the  other  hand,  ot  cytoplasmic domain-dependent 
changes in cell adhesion may be due to alterations of ligand- 
binding affinity. For example, others have demonstrated that 
agonist-stimulated cell adhesion correlated with integrin con- 
formational changes (72, 73), and cytoplasmic tail mutations 
resulted in altered ligand-binding constants (42). Although 
it bypasses normal cellular regulation mechanisms, the anti- 
31 Ab TS2/16 and other similar Abs can stimulate cell adhe- 
sion, most likely by causing an increase in integrin affinity 
(23,  74, 75), thus providing another precedent for upregu- 
lated adhesion through modulation of integrin affinity. 
To determine whether regulation through ot chain cyto- 
plasmic domains does or does not involve alteration in integrin- 
ligand binding affinity, direct affinity measurement will be 
required. However, multiple attempts at direct ligand binding 
of CS1 peptide to VLA-4 have thus far proven unsuccessful 
because of high levels of nonspecific binding. 
Regardless  of  whether  ~  chain  cytoplasmic  domains 
influence integrin affinity, it is clear that their role is not highly 
specific since three different sequences (oF, ot  4, and ot  s) were 
interchangeable. Whereas the details of the roles of oe chain 
cytoplasmic domains remain to be elucidated, we suggest that 
o~ chain-specific association with other proteins, or specific 
phosphorylation events are unlikely, given the extent of se- 
quence divergence. Most likely, the role of these ol chains 
in regulating cell adhesion is closely connected with the role 
of the 31 cytoplasmic domain. Previous work has indicated 
that the cytoplasmic domains of 31 (76) and Bz (40, 41) are 
also very important for regulating integrin contributions to 
657  Kassner  and Hemler normal and agonist-stimulated cell adhesion. Notably, al- 
though the specific sequences of three different c~ chain cyto- 
plasmic domains are interchangeable with respect to integrin- 
mediated cell adhesion, in other functional contexts, involving 
cell migration and collagen gel contraction,  the ot  4 cyto- 
plasmic domain appeared to be quite distinct from those of 
ot  2 and ot  5 (52). 
In conclusion, our data establishes that the c~ chain cyto- 
plasmic domain plays a critical positive role in determining 
the level of adhesive function of VLA-4 and perhaps other 
B1 integrins. Although its exact identity is not critical, the 
presence  of an ot chain cytoplasmic domain is essential  for 
the integrin to manifest the full activity permitted by the 
cellular environment in which it is expressed. We postulate 
that the o~ chain cytoplasmic domain is involved in "inside- 
out" signaling, such that cellular factors acting at least partly 
through the c~ chain cytoplasmic domain are altering the ex- 
ternal conformation of the c~4~t heterodimer and therefore 
controlling the level of both constitutive and agonist stimu- 
lated integrin function. 
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